Clinical trial of lifestyle interventions for weight management in adults living with MS
Obesity can increase the risk of developing MS and may increase levels of disability in those with established MS. Losing weight can help improve more than just body size, but it can be difficult to do and needs the support of a healthcare team to aid behaviour change. This study will use a tested method […]
STRONG-MS: Bone health and muscle health in MS
This study is a randomised controlled trial evaluating ONERO™. This is a High-intensity Resistance and Impact Training (HiRIT) exercise intervention that has potential benefits for bone health and muscle strength in people with (MS). Qualified physiotherapists will supervise balance exercises, impact movements and weightlifting in twice-weekly, 45-minute sessions. Participation involves a total of 24 months. […]
Multiple Sclerosis and the NDIS: What Does and Doesn’t Work?
These interviews are part of a larger project titled ‘Assessing the impact of the National Disability Insurance Scheme (NDIS)’, funded by MS Australia. It is the first of its kind to produce an overview of National Disability Insurance Scheme (NDIS) access for people with multiple sclerosis in Australia. These interviews will explore the challenges and […]
Fatigue In Relapsing Multiple Sclerosis – Epstein Barr Virus (FIRMS-EBV) Treatment Trial
Fatigue is a common symptom for many people with MS and it does not respond to traditional MS treatments. It has been suggested that fatigue in MS could relate to chronic infection with the Epstein Barr Virus (EBV). In this clinical trial, two drug therapies with antiviral effects against EBV will be tested for their […]
Phase III, multicentre, randomised, double-blinded, placebo-controlled, MAMS trial of SpironolacTone and famciclOvir in the treatment of Progressive MS to prevent disability progression (STOP-MS)
Multiple sclerosis (MS) is a potentially devastating disease of the central nervous system and progressive MS, which occurs in up to two-thirds is the most severe form. Current therapies for MS have limited effect in the progressive stage. Recent studies have confirmed that the primary cause of MS is latent infection with Epstein-Barr virus (EBV). […]